Triage At NIH: A Smoke Screen Concealing The Real Problems Facing American Science

The National Institutes of Health's effort to streamline its peer-review process by virtually dismissing, after cursory examination, as many as half the research proposals it receives is not a good idea. This experiment at whatUs come to be known as "triage" will not solve any of the problems facing United States science; indeed, it will create new ones. Theoretically, early-stage identification and rejection of "noncompetitive" ap

Written byEacute Musacchio
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The National Institutes of Health's effort to streamline its peer-review process by virtually dismissing, after cursory examination, as many as half the research proposals it receives is not a good idea. This experiment at whatUs come to be known as "triage" will not solve any of the problems facing United States science; indeed, it will create new ones.

Theoretically, early-stage identification and rejection of "noncompetitive" applications would relieve the pressure that burdens NIH scientific review administrators, project officers, and auxiliary staff who are overworked, demoralized, and under considerable stress. Reviewers, it is hoped, would have more time and presence of mind to consider in depth those comparatively few applications deemed at first glance to be especially virtuous.

However, reviewers' demoralization cannot be attributed to the large number of applications they must deal with; they are used to putting in grueling, 12-hour days. That is one of the qualifications for the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies